Hemogenyx Pharmaceuticals Plc (HOPHF) Research

Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments. Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies. Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.

Market snapshot

Symbol
HOPHF
Price
$2.33
Day change
0.00%
Market cap
$55.7M
P/E ratio
-5.07x
52-week range
0.04-2.33
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Advanced Proteome Therapeutics Corporation (APTCF)
  • CuraScientific Corp (CSTF)
  • TuHURA Biosciences, Inc. (HURA)
  • Kiromic BioPharma, Inc. (KRBP)
  • Evome Medical Technologies Inc. (LNDZF)
  • ProSomnus, Inc. (OSA)
  • Predictive Technology Group, Inc. (PRED)
  • Pivotal Therapeutics Inc. (PVTTF)

Open Hemogenyx Pharmaceuticals Plc (HOPHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.